Complex coronary cases
PCI of SVG to OM1 – April 2012
Views 1106

68-year old male with prior CABG x1 + AVR in 2005, presented new onset crescendo angina CCS Class III. A stress MPI revealed large anteroapical and moderate inferolateral ischemia. Cardiac cath on March 20, 2012 revealed 3 vessel CAD, stenosed SVG to OM1, normal LV function and normal aortic bioprothesis. He underwent successful intervention of culprit mid and distal LAD using Xience V DES and Tryton BMS in D2 under Tryton bifurcation Trial. Patient is now planned for PCI of SVG to OM1.

1:09:02

Q&A
Q
Can you briefly decribe the Tryton trial?
A.

Tryton trial is comparing a dedicated sidebranch bare metal stent with PTCA only of sidebranch with DES in the main vessel in both the groups.


Q
Would there be a role for FFR in this situation?
A.

Not in the Tryton trial but certainly in the usual day to PCI; FFR is playing a major role to see if we should go after the sidebranch many of them just look hazy and of borderline stenosis.


Q
In the next decade, with the expansion of hybrid labs, do you see the complete demise of use of SVG?
A.

Not really as many of complex CAD such as heavily calcified lesions and CTO's still will require CABG.


Q
How many hybrid procedures does your institution do?
A.

Very little. May be 4-5 per year.


Q
What is your algorithm - first PCI, then LIMA-LAD?
A.

Best approach is first LIMA to LAD and then PCI just a day before the discharge. Hence CABG can be done while pt is not on plavix.


Q
What is your anti-coagulant strategy during hybrid procedures?
A.

All cases with Bivalirudin and avoid GP IIb/IIIa inhibitors. Clopidogrel is preferred ADP receptor blocker.


Q
Is there problems with insurance reimbursements for the hybrid procedures?
A.

So far we have not encountered the insurance barrier for hybrid cases.


Q
Do you see a decline for emboli protection devices for SVG management?
A.

agree with the statement that despite the Class I recommendation for DPD use in SVG PCIs, they are needed in only <25% of the cases. That exactly is the national trend as per ACC-NCDR data.


Q
What are your biggest concerns about the M-Guard device?
A.

Biggest concern about M-guard device is that it is not coated with the antiproliferative drug at this time.


Q
Of all emerging technologies for SVG treatment, which appears the most promising to you?
A.

Still M-guard stent has the best promise as there are not much emerging technology in the field of SVG PCI.


comments

Leave a Reply

Your email address will not be published. Required fields are marked *

suggestion
Suggestions
Staged PCI of RCA multilayer DES CTO ISR using rotational atherectomy and IVBT – November 2020
Views 266

Case and Plan: 65-year old male with known long standing history of chronic ischemic heart disease requiring multiple PCI’s over the years after declining CABG, presented with CCS Class III angina and high risk stress MPI for multivessel ischemia. A Cardiac Cath on September 28, 2020 revealed 3 V CAD: 100% proximal RCA due to […]


Complex Multivessel PCI in a High SYNTAX Score Patient – October 2020
Tags: | |
Views 346

Case and Plan: 74-year-old obese male on HD presented with CCS Class II angina and positive SPECT MPI on July 14, 2020 done as pre-op for renal transplant revealing moderate apical, inferior and inferolateral ischemia. A Cardiac Cath on August 20, 2020 revealed 3 V CAD: 70% mid RCA, 100% RCA-AV Cont, subtotal calcified mid-distal […]


Radial PCI of Long Complex Calcified LAD post TAVR – September 2020
Views 270

Case and Plan: 78 year-old-male presented on August 7, 2020 with progressive exertional dyspnea, NYHA class III. Workup revealed severe AS (AVA 0.7cm2), normal LV function and STS mortality of 1.1%. After heart team discussion, patient underwent successful TAVR using 26mm SAPIEN-3 Ultra with excellent results, AV area of 2.0cm2 and no PVL. A coronary […]


Stent Ablation with RA of Underexpanded Multilayer DES – August 2020
Tags: | |
Views 442

63 year-old male with known CAD, CABG x2 (1999) and multiple PCI’s to SVG to RCA and LCx branches presented with CCS Class IV angina and non-STEMI (TnI 1.2U). A Cardiac Cath on June 22, 2020 revealed patent LIMA to LAD, non obstructive LCx branches with patent prior stents and 90% multilayer in-stent restenosis of […]